Mitigation of radiation-induced esophageal fibrosis by macrophage-targeted phosphatidylserine-containing liposomes with partial PEGylation
Abstract
Radiation-induced fibrosis (RIF) is a major complication following radiotherapy treatment. Macrophages are the key regulators of inflammatory responses and have emerged as critical targets for the prevention of fibrosis. This study evaluated the efficacy of PEGylated phosphatidylserine-containing liposomes (PEG-PSLs) in mitigating RIF by modulating macrophage activity. PEG-PSLs influenced the polarization of bone marrow-derived macrophages (BMDMs), reducing the expression levels of inflammatory cytokines and fibrosis-associated markers. These effects were observed within a specific PEGylation range, with the greatest reduction achieved at 1–1.5mol% PEG. Analysis of the IL-4-induced JAK-STAT signaling pathway indicated that the PEG-PSL-mediated suppression occurred at or beyond the point of JAK-1 phosphorylation. In in vitro fibrosis assays, PEG-PSLs reduced fibroblast-to-myofibroblast and epithelial-to-mesenchymal transitions when co-cultured with BMDMs. In vivo studies using a rat model of esophageal irradiation demonstrated that PEG-PSLs effectively attenuated fibrotic progression, preserved tissue architecture, and enhanced muscle regeneration. These findings indicate the potential of partially PEGylated phosphatidylserine liposomes as therapeutic agents for mitigating post-irradiation esophageal fibrosis.
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.